Patents by Inventor Shangzi Wang

Shangzi Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220257609
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Application
    Filed: February 23, 2022
    Publication date: August 18, 2022
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. SMITH, Louis WEINER, Sandra JABLONSKI, Sandeep NADELLA, Shangzi WANG
  • Patent number: 11278551
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 22, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Publication number: 20200383996
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. Also provided are methods for increasing sensitivity of a (CCK) receptor-expressing cancerous tumor in a subject to immunotherapy.
    Type: Application
    Filed: March 15, 2018
    Publication date: December 10, 2020
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Patent number: 9567641
    Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 14, 2017
    Assignees: SAMSUNG ELECTRONICS CO., LTD., GEORGETOWN UNIVERSITY
    Inventors: Bo Gyou Kim, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner
  • Publication number: 20150010575
    Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Inventors: Bo Gyou KIM, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner